Novo Nordisk launches obesity drug Wegovy

Novo Nordisk launches obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market. A spokesperson for the Danish drugmaker confirmed the news to Reuters after it was first reported by China-based financial media outlet Yicai.
Novo’s Wegovy Launched in China at a Fraction of US Price
Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine for about $193.27 for a one-month supply.
Weight-loss drug Wegovy launched in China
Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound.
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
Novo Nordisk’s Blockbuster Wegovy Drug Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
Novo Nordisk reportedly launches Wegovy in China
Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly (LLY). Read more here.
Benzinga.com16h
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than ...
24/7 Wall St7d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
NBC Los Angeles12d
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...